Kornimate/medical-research-clean huggingface dataset:
movement and music intervention for individuals with dementia

Conditions: Dementia With Lewy Bodies; Dementia

Summary: the goal of the study is to learn about how possible benefits of movement and music for individuals with dementia. individuals with dementia will participate in a dance class. the study includes assessments of walking, balance and cognition.

dementia impacts 5%-7% of individuals \>60 years old. it impacts the person's ability to perform work, care for him/herself and ultimately leads to physical disability. there is a high caregiver burden associated with dementia and many individuals require care in a long-term care facility. there is some emerging evidence that music based interventions may have a protective effect on the brain in those with dementia. there is also evidence that doing activities that engage the brain through music are beneficial. this study seeks to investigate the potential benefits of a music based intervention for individuals with dementia. the study aims to recruit individuals with a diagnosis of dementia. once enrolled participants will undergo assessment of walking, balance and cognition and then be asked to participate either in a dance class or to listen to live music. after 6 weeks and again at the end of the study (after 12 weeks) participants will undergo assessments of walking, balance and cognition.

Eligibility criteria:
inclusion criteria: * diagnosis of dementia * mini-mental state examination score \> 9 * age \> 60 years * able to follow simple instructions exclusion criteria: * unable to walk 10 feet unassisted * presence of orthopedic disorder that impacts walking * presence of other neurologic diagnosis that impacts cognitive or motor function such as stroke, parkinson disease or traumatic brain injury

Keywords: dementia
combined modality therapy in hepatoblastoma: south egypt cancer institute experience

Conditions: Hepatoblastoma

Summary: the aim of this study is to retrospectively investigate the effect of combined modality treatment of pediatric hepatoblastoma and the factors affecting the prognosis in accordance with the experience at the pediatric oncology department at south egypt cancer institute.

background: hepatoblastoma (hb) is the most common malignant liver tumor in children, with an incidence of 0.7 to 1 per million children \<15 years of age. till 1970s, surgery was the primary modality of treatment of hb. unfortunately, up to 60% of the patients present in an unresectable stage. later, the chemo- responsiveness of the tumor was demonstrated which led to the incorporation of adjuvant chemotherapy with cisplatinum and doxorubicin in the treatment of hb. international society of pediatric oncology (siop) pioneered the concept of neoadjuvant chemotherapy in the management of hb. patients \& methods: in the period from 2002 january till 2016 january, retrieval \& analysis of the medical records of pediatric patients with hepatoblastoma will be made at the pediatric oncology department, south egypt cancer institute which represents the largest referral center in upper egypt. after pathologic confirmation of the diagnosis, these data will be categorized according to patients' demographics, presenting features, laboratory studies, including tumor markers \& histologic subtype, radiographic evaluation, disease staging, treatment course given, and subsequent treatment outcomes.

Eligibility criteria:
inclusion criteria: * patients whose age less than 19 years. * patients diagnosed with hepatoblastoma. exclusion criteria: * patients whose age more than 18 years.

Keywords: childhood cancer pediatric oncology
esketamine for fibromyalgia treatment

Conditions: Fibromyalgia

Summary: fibromyalgia is a cause of chronic pain, classified by the internal classification of diseases (icd) as a primary chronic pain with specific diagnostic criteria established by the american college of rheumatology (acr). no treatment to its complete cure is available at this time, all treatments having as purpose pain relief and an improvement of quality of life by combining pharmacologic and nonpharmacologic treatments. one of the mechanisms proposed in fibromyalgia is the central sensitisation phenomenon, by which the central nervous system becomes "hypersensitive" to nociceptive or non-nociceptive stimuli. the receptor involved in this phenomenon is the n-methyl-d-aspartate receptor to which ketamine binds. ketamine has therefore been proposed as a co-treatment in chronic pain with central sensitization phenomena, such as fibromyalgia.

ketamine is a drug used for anesthesia since the 1970s, acting as an antagonist to the n-methyl-d-aspartate receptor located in the central nervous system. it has two stereoisomers : r +ketamine and s - ketamine, the latter being about two to four times more potent. s-ketamine also has the advantages of producing less psychotropic effects, less tiredness and a lower temporary cognitive impairment than the racemic mixture at equianalgesic doses. being first used as an anesthetic, in the last twenty years, ketamine's indications expanded to other domains, such as treatment of depression or off label use for chronic pain relief. chronic pain is a multidimensional syndrome that touches 17-44% of the population of western countries. fibromyalgia is a cause of chronic pain, classified by the internal classification of diseases (icd) as a primary chronic pain with specific diagnostic criteria established by the american college of rheumatology (acr). no treatment to its complete cure is available at this time, all treatments having as purpose pain relief and an improvement of quality of life by combining pharmacologic and nonpharmacologic treatments (as given by the european league against rheumatism (eular) guidelines). one of the mechanisms proposed in fibromyalgia is the central sensitisation phenomenon, by which the central nervous system becomes "hypersensitive" to nociceptive or non-nociceptive stimuli. the receptor involved in this phenomenon is the n-methyl-d-aspartate receptor to which ketamine binds. ketamine has therefore been proposed as a co-treatment in chronic pain with central sensitization phenomena, such as fibromyalgia.

Eligibility criteria:
inclusion criteria: * patients suffering from chronic pain (as defined by international association for the study of pain) being diagnosed as fibromyalgia according to the american college of rheumatology 2016 criteria * patients qualified for the treatment by s-ketamine as established by our latest clinical practice * patients aged 18-65 years old
evaluation of fanconi syndrome and cystinosis

Conditions: Cystinosis; Fanconi Syndrome

Summary: objectives: i. classify renal tubular defects using clinical and biochemical findings in patients with fanconi syndrome and cystinosis.

protocol outline: patients receive a clinical and biochemical evaluation, including a psychometric assessment and molecular, renal, and thyroid studies.

Eligibility criteria:
* inherited renal tubular defects, i.e., fanconi syndrome * fanconi syndrome due to cystinosis eligible

Keywords: fanconi syndrome cystinosis rare disease renal and genitourinary disorders
platelet rich therapy for facial rejuvenation

Conditions: Facial Rejuvenation

Summary: this study will be a prospective study of patients who undergo platelet-rich therapy (prt) for facial rejuvenation at nyu langone medical center. prt has been increasingly used for wound healing, fat grafting, hemostasis as well as facial enhancement. prt involves injection of patient's own platelets and fibrin, and has evolved as a less invasive technique for facial rejuvenation compared to more traditional techniques. through the use of pre and post treatment photos, in addition to the face-q questionnaire and a clinician assessment, it is our hope that we will confirm the rejuvenating capabilities of prt.

to assess patient-reported satisfaction of using platelet rich therapy for facial rejuvenation using a validated questionnaire (the face-q scale). this is a prospective study of patients who will undergo platelet-rich therapy for facial rejuvenation at nyu langone medical center. platelet rich therapy (prt) has been increasingly used for wound healing, fat grafting, hemostasis as well as facial enhancement. prt involves injection of patient's own platelets and fibrin, and has evolved as a less invasive technique for facial rejuvenation compared to more traditional techniques. however, while platelet rich therapy for facial enrichment continues to gain popularity; little evidence exists to support its use in the current literature. therefore, this study sets out to determine patient satisfaction as well as quality of life following prt for facial rejuvenation. prt has been previously used successfully in facial plastic surgery and is being offered as an option as part of standard of care for facial rejuvenation (sclafani). subjects will be identified by the principal investigator as they present to the office for facial rejuvenation and are interested in an alternative to soft tissue fillers. all such patients will be given prt as an alternative option for facial rejuvenation and any patient who agrees to this therapy will be enrolled in the study. subject enrollment will continue until a total of 30 subjects are recruited.

Eligibility criteria:
inclusion criteria: * males and females * ages 21 - 80 * patients of all racial and ethnic origins * patients of dr. hazen undergoing facial rejuvenation exclusion criteria: * patients undergoing facial rejuvenation using other methods including botox injections, chemical peels, face lifts and others. * patients using blood thinners that cannot be stopped * patients who have used aspirin within a week of the procedure date

Keywords: face-q platelet rich therapy prt
serial flt pet imaging in cancer patients for monitoring of response to therapy

Conditions: Histologically-confirmed Malignancies

Summary: the purpose of this study is to see if pet/ct scans that use a radioactive substance called \[18f\] fluorothymidine (flt), can detect and monitor changes in the tumor. radioactive substances are used with pet/ct scans to "see" cancer cells, and are also called radiotracers. flt is a new radiotracer that has been given to people in prior studies. flt pet/ct is an experimental scan unlike fdg (fluorodeoxyglucose) pet scan which is a standard clinical scan and is commonly used. the investigators would like to know if there is any evidence of early treatment response by obtaining fltpet/ ct scans before and after treatment.

this protocol is an "umbrella" or "companion" protocol to be used in conjunction with other protocols that are evaluating treatment response in solid or hematologic malignancies. the aim of this protocol is to determine if pet imaging with the proliferation marker 18fflt can monitor changes in flt uptake parameters, in particular changes in the standardized uptake value (suv), within tumor target lesions.

Eligibility criteria:
inclusion criteria: * patients with histologically-confirmed (confirmation done at mskcc) malignancies. * patients who have consented to a therapeutic protocol for the treatment of their cancer. * patients must be ≥ 18 years old. exclusion criteria: * patients who cannot undergo pet/ct scanning (i.e. because of weight limits, claustrophobia). * women who are pregnant or breast-feeding.

Keywords: flt pet imaging 3'deoxy-3' [18f] fluorothymidine ([18f] flt) ct scans 14-050
prospective study of palonosetron in radiation induced nausea and vomiting (rinv)

Conditions: Nausea; Vomiting

Summary: this phase ii study will investigate the use of palonosetron in the efficacy of prophylaxis or rescue of single or multiple fraction radiation induced nausea and vomiting. this prospective study employs a parallel arm design, allowing for inclusion of patients with pre-existing nausea and vomiting versus no current nausea or vomiting. eligible patients receiving radiotherapy known to have a low or moderate emetogenic risk will receive every other day dosing of 0.5 mg palonosetron for the length of treatment. nausea, vomiting, use of rescue medication, and impact on quality of life will be monitored during and after radiation treatment completion.


Eligibility criteria:
inclusion criteria: * informed consent * patient will receive radiation therapy to considered moderate risk (upper abdomen, upper and half body irradiation) or low risk (lower thorax and pelvis) emetogenic palliative radiotherapy. * patients will be grouped according to nausea and vomiting status at baseline as follows: * group 1: patient is experiencing no nausea and vomiting at baseline * group 2: patient is experiencing at least mild nausea and/or at least mild vomiting at baseline exclusion criteria: * patient is scheduled to receive cranial radiation therapy during or within 10 days following completion of protocol rt. * patient received cranial rt within 7 days prior to commencement of protocol rt. * patient is scheduled to receive chemotherapy during or within 10 days following completion of protocol rt. * patient received moderately or highly emetogenic chemotherapy within 7 days prior to commencement of protocol rt. * patient is scheduled to change regimen/dose or start the use of low dose corticosteroids (inhaled or topical permitted), or other medications considered to have antiemetic properties within 48 hours prior to protocol rt. * patient is scheduled to change regimen/dose or start the use of low dose corticosteroids (inhaled or topical permitted), or other medications considered to have antiemetic properties during or within 10 days following completion of protocol rt. * concurrent use of corticosteroids during protocol rt is not permitted, unless low dose corticosteroids (hydrocortisone) are used for cancer treatment * patient is allergic to protocol medication. * patient has a karnofsky performance status score \<40. * patient is a woman who is pregnant or of childbearing potential and is not using contraceptive measures.

Keywords: nausea vomiting radiation anti-emetic drug
conservative treatment versus elective repair of umbilical hernia in patients with ascites and liver cirrhosis

Conditions: Umbilical Hernia; Liver Cirrhosis; Ascites

Summary: the purpose of the present study is to investigate whether or not to perform elective surgical repair of umbilical hernias in patients with liver cirrhosis and ascites. there are no other randomized controlled trials in this area. the optimal management in patients with umbilical hernias and liver cirrhosis with ascites is not clear yet. the general surgical opinion is that umbilical hernias in patients with ascites should not be corrected because of the supposedly high operative risks and high recurrence rates. conservative treatment, however, can have severe complications resulting in emergency repair. such operations carry a higher risk of complications than elective operations, particularly in this group of patients. prospective and retrospective series showed us that elective hernia repair in this specific patient group is safe without major complications or high recurrence rates. the aim of this study is to asses the optimal timing of correction of umbilical hernia in patients with liver cirrhosis and ascites.


Eligibility criteria:
inclusion criteria: * primary umbilical hernia * liver cirrhosis * ascites (us proven) * age ≥ 18 years * signed informed consent exclusion criteria: * recurrent umbilical hernia * midline laparotomy in medical history * asa1 score iv or above * incarcerated hernia related emergency procedures * patent umbilical vein; \>5mm * expected time to ltx \<3 months

Keywords: umbilical hernia cirrhosis ascites conservative surgery optimal management
comparing caf and tcaf with soft tissue grafting for treating multiple recessions in the premandibula.

Conditions: Gingival Recession, Localized; Gingival Recession, Plastic Surgery; Gingival Recessions; Gingival Recession, Mucogingival Surgery

Summary: multiple techniques can be used for recession coverage. the most common techniques are : tunnel technique (t), coronally advanced flap (caf) or a combination of both (tcaf). tunnel and coronally advanced flap are frequently used in clinical practice, whereas the combined technique is a rather recent developed surgical approach. this randomized controlled trial compares caf and tcaf to determine which technique provides better root coverage for receding gums in the lower front teeth. the main question it aims to answer is: - what is the average root coverage achieved with each technique in the short and long term? this may be clinically relevant because covering gum recession can reduce tooth sensitivity, improve aesthetics and make oral hygiene easier. researchers will compare the coronally advanced flap (caf = the gum is detached and repositioned higher) with the tunneled coronally advanced flap (tcaf = the gum is undermined, only partially detached and repositioned higher). in both techniques, a small piece of tissue is removed from the palate, which is used to cover the recession. the purpose of the connective tissue graft under the flap/tunnel is to increase thickness and provide support. participants will: * undergo surgery (caf or tcaf, randomly assigned) to cover recessions * attend regular check-ups for up to 10 years after surgery * keep a postoperative journal (recording medication use, pain levels, tooth sensitivity, etc.)


Eligibility criteria:
inclusion criteria: * at least 18 years old * good oral hygiene * presence of at least 2 recessions in the premandible * good general health exclusion criteria: * smoker * pregnant women (assessed at each visit; if the patient appears pregnant during follow-up, x-rays will not be taken)

Keywords: tcaf tunneled coronally advanced flap caf coronally advanced flap multiple adjacent gingival recessions magr premandible
cardio-metabolic risk factors, osteoporosis and thrombus embolic assessment, along woman's life

Conditions: Women's Health

Summary: background: it is well known that health risks change during lifespan. the weight of a single risk factor increases with aging. the clinical significance of a single risk factor is clear but there is a lack on the effectof multiple risk factors linked together along different hormones condition of women's life in particular regarding to metabolic syndrome, osteoporosis, and thromboembolic risk. aim: 1) characterization and follow up of cardiometabolic risk in women of childbearing age; 2) characterization and follow up of cardiometabolic risk and osteoporosis in menopausal-transition women and in post-menopausal women;

background: it is well known that health risks change during lifespan. the weight of a single risk factor increases with aging. the clinical significance of a single risk factor is clear but there is a a lack on the effectof multiple risk factors linked together along different hormones condition of women's life in particular regarding to metabolic syndrome, osteoporosis, and thromboembolic risk. moreover some pathological but reversible conditions during pregnancy may represent an incursion in metabolic syndrome and a sing of future cardiovascular disease. aim: 1) characterization and follow up of cardiometabolic risk in women of childbearing age; 2) characterization and follow up of cardiometabolic risk and osteoporosis in menopausal-transition women and in post-menopausal women; in outpatients referring to ftgm ambulatory of cardiovascular gynecology and osteoporosis in pisa.

Eligibility criteria:
inclusion criteria: * outpatients referred to the gynecologic endocrinology and osteoporosis unit of fondazione cnr-regione toscana g. monasterio, pisa, italy, who have authorized the use of their personal data exclusion criteria: * history of/or current neoplastic disease
trial of cannabis for essential tremor

Conditions: Essential Tremor

Summary: this is a pilot trial to evaluate the safety and efficacy of a combined oral formulation of thc and cbd in patients with essential tremor.

essential tremor (et) is the most common neurological movement disorder, affecting up to 1% of the population and up to 5% of individuals over the age of 65. et is characterized by often disabling tremors that occur when an individual moves. the tremors most commonly affect the hands, head, voice, and legs in order of frequency, leading to impairment in activities of daily living and morbidity. no pharmacological agent has been developed for et, though existing agents such as propranolol and primidone are used off-label to reduce tremor amplitude. deep brain stimulation surgery is often reserved for only individuals with the most severe tremors. patients with et have long reported tremor benefits with the use of cannabis, though no controlled trials have been conducted. the investigators plan to conduct the first double-blind, placebo-control clinical trial of cannabis in an oral capsule. various validated tremor rating methods will be used to quantify tremor severity, while looking at tolerability and safety.

Eligibility criteria:
inclusion criteria: * diagnosis of et by a movement disorder neurologist * stable dose of tremor medication for a period of at least 6 weeks prior to screening * tremor in the arms * tremor(s) is/are moderately severe (amplitude of at least 1cm) exclusion criteria: * significant non-et related abnormal findings on neurological exam * tremor at rest, or other features suggestive of parkinson disease * diagnosis of dementia * pregnant or nursing * childbearing potential and unable or unwilling to use contraception during course of the trial * on medications known to interact with the study drug * current or prior history of alcohol or substance abuse * recent exposure to primidone (within the past 21 days) or benzodiazepines (such as valium, ativan or klonopin), ketoconazole, ritonavir, clarithromycin, rifampin, carbamazepine, st. johns wort, digoxin or other medications known to affect your liver enzymes (within the past 7 days). * unwilling to abstain from consuming grapefruits, grapefruit juice or grapefruit containing products. * taking medications such as warfarin, cyclosporine, and amphotericin b that are highly protein-bound * do not wish to take a cannabis-derived agent * allergy or sensitivity to sorbitol, xylitol, stevia or other natural sweeteners * allergy or sensitivity to cannabis * used cannabis or a cannabis-derived product (such as cbd oil) within the past 4 weeks or plan to use it during this research study. * diagnosis of a psychiatric disorder (e.g., mania, bipolar depressive disorder, schizophrenia, schizoaffective disorder, or other major psychiatric disorder) * current or prior history of suicidal thoughts and/or behavior * active medical problem affecting the immune system, liver, gastrointestinal tract, lungs, heart, endocrine system (such as diabetes and/or thyroid), and/or a blood clotting disorder * current infection * reduced kidney function (gfr \<60)
dose ranging study of bms-945429 in subjects with moderate to severe crohn's disease

Conditions: Crohn's Disease

Summary: the purpose of this study is to characterize the safety, efficacy and dose response of bms-945429 in subjects with moderate to severe crohn's disease and who have had an insufficient response to conventional therapy or have failed anti-tumor necrosis factor (anti-tnf) therapy.


Eligibility criteria:
inclusion criteria: * confirmed crohn's disease diagnosis via radiology, endoscopy or histology within prior 12 months. diagnosed for at least 3 months * active disease with crohn's disease activity index (cdai) ≥ 220 and ≤ 450 * failed conventional therapy or steroid dependent exclusion criteria: * diagnosed/clinical findings of ulcerative colitis (uc), indeterminate colitis, non colonic/ileal disease * stricture/stenosis, stoma, proctocolectomy, subtotal colectomy, ileorectal anastomosis * history of diverticulitis, or evidence of gastrointestinal (gi) perforations